수혈 세트 시장 : 시장 예측(2026-2032년)

The Blood Administration Set Market is projected to grow by USD 18.10 billion at a CAGR of 8.87% by 2032.

Blood Administration Sets: Executive Overview

Blood administration sets are sterile, single-use devices designed to support the controlled transfusion of blood and blood components. Their performance depends on reliable fluid pathways, filtration, compatibility with transfusion equipment, secure connections, and clear identification. Demand is shaped by transfusion activity, surgical care, trauma response, oncology, maternal health, and hospital infection-prevention requirements. The market is therefore closely connected to healthcare capacity, blood-bank operations, procurement standards, and the quality of clinical supply chains.

Safety, Standardization, and Supply Resilience Are Reshaping the Landscape

The landscape is shifting toward stronger emphasis on patient safety, traceability, interoperability, and consistent product quality. Healthcare providers increasingly evaluate sets through the combined lens of filtration performance, leakage prevention, ease of priming, compatibility with pumps and connectors, packaging integrity, and workflow efficiency. Regulatory scrutiny and hospital protocols are also reinforcing the importance of validated manufacturing, sterile barriers, lot-level traceability, and documented post-market surveillance.

Procurement priorities are evolving alongside supply-chain lessons from recent disruptions. Hospitals and blood services are placing greater value on qualified secondary sources, regional inventory visibility, standardized product specifications, and continuity planning. Sustainability is also becoming more relevant, although infection-control requirements mean that material changes must be assessed carefully against sterility, performance, and disposal obligations.

Artificial Intelligence Improves Forecasting, Quality Control, and Transfusion Workflows

Artificial intelligence can influence blood administration set operations indirectly by improving the systems that determine when, where, and how transfusion supplies are needed. Predictive analytics can combine procedure schedules, blood utilization, inventory records, seasonal demand, and emergency activity to support replenishment planning and reduce avoidable shortages or excess stock. In hospitals, decision-support tools may also help coordinate blood-bank workflows, equipment availability, and documentation requirements.

Manufacturing applications include computer-vision inspection for packaging defects, tubing anomalies, connector quality, and particulate concerns, as well as analytics for process monitoring and maintenance. These tools should remain subject to validation, cybersecurity controls, human oversight, and applicable medical-device requirements. AI can strengthen consistency and visibility, but it does not replace clinical judgment, sterile manufacturing controls, or established transfusion protocols.

Regional Insights: Diverse Regulatory and Care-Delivery Priorities

North America emphasizes stringent quality systems, hospital standardization, traceability, and integration with sophisticated blood-bank and surgical workflows. Europe places strong weight on harmonized regulatory expectations, patient safety, sustainability considerations, and procurement alignment across public healthcare systems. Asia-Pacific combines advanced hospital markets with rapidly expanding healthcare capacity, creating varied needs for affordability, local supply resilience, and scalable transfusion infrastructure.

Latin America is influenced by uneven healthcare access, public procurement cycles, and the need for dependable products across centralized and decentralized services. The Middle East is shaped by investments in specialized hospitals, emergency preparedness, and imported medical-device supply chains, while the GCC generally benefits from coordinated healthcare development. Africa presents a strong need for robust, accessible transfusion infrastructure, dependable distribution, appropriate storage and handling practices, and products suited to resource-constrained settings. Across all regions, training and blood-safety systems are as important as device specifications.

Group Insights: Procurement and Regulatory Alignment Vary by Bloc

ASEAN markets reflect differing levels of regulatory maturity, healthcare infrastructure, and local manufacturing capability, making adaptable compliance and distribution strategies important. BRICS members combine major healthcare systems with distinct regulatory pathways, domestic-industry policies, and public procurement structures; suppliers must therefore avoid assuming a single regional operating model. The European Union benefits from regulatory coordination and cross-border standards, while national purchasing practices and hospital requirements still influence adoption.

The G7 generally places substantial emphasis on evidence, quality management, infection prevention, sustainability, and supply continuity. GCC healthcare systems often prioritize advanced clinical capacity, centralized purchasing, and dependable international logistics. NATO countries are not a single medical-device market, but shared concerns around emergency preparedness, interoperability, and resilient medical supply chains can affect institutional planning. Across these groups, compliance mapping and local stakeholder engagement remain essential.

Country Insights: Local Systems Shape Product Requirements

Australia and Canada emphasize regulated procurement, geographically resilient distribution, and reliable hospital supply. Brazil and Mexico face diverse public and private healthcare requirements, with local registration, procurement complexity, and distribution reach influencing access. China combines large-scale hospital demand with evolving domestic-device capabilities and regulatory expectations, while India requires solutions that can serve highly varied facility sizes, budgets, and transfusion workloads.

France, Germany, Italy, Spain, and the United Kingdom place strong emphasis on quality assurance, clinical governance, and public-sector purchasing processes, with differences in national implementation and reimbursement environments. Japan and South Korea are characterized by advanced hospital infrastructure, exacting quality expectations, and interest in efficient, dependable workflows. Russia's healthcare-device environment is affected by regulatory, procurement, and supply-chain conditions. In the United States, hospital networks, blood centers, accreditation requirements, and evidence-based purchasing strongly influence product selection.

Actions for Leaders: Build Safety, Resilience, and Evidence Into Strategy

Industry leaders should first align product development with verified clinical and operational needs: dependable filtration, secure connections, intuitive handling, packaging integrity, and compatibility with commonly used transfusion equipment. Quality systems should include robust supplier qualification, validated sterilization, lot traceability, complaint analysis, and contingency plans for critical components. Regional regulatory requirements should be mapped before launch rather than treated as a post-development activity.

Commercial and operational strategies should pair reliable distribution with customer education for blood banks, nurses, procurement teams, and biomedical staff. Leaders should use demand and inventory analytics responsibly, establish measurable service-level indicators, and assess sustainability claims through lifecycle evidence. Partnerships with healthcare institutions can support workflow validation, while transparent post-market monitoring can strengthen trust and identify improvement opportunities without overstating clinical benefits.

Research Methodology: Evidence-Based Market Assessment Framework

This executive summary is structured around the supplied market definition for blood administration sets and the required geographic and group lenses. The assessment considers device function, transfusion workflows, regulatory and quality expectations, healthcare infrastructure, procurement behavior, supply-chain resilience, and the potential operational role of artificial intelligence. Regional, group, and country observations are framed as qualitative comparisons rather than numerical market claims.

A rigorous full study would triangulate official regulatory publications, standards, hospital and blood-service guidance, peer-reviewed clinical and engineering literature, procurement documentation, manufacturer quality information, and interviews with qualified healthcare stakeholders. Findings should be cross-checked for publication date, jurisdiction, methodological quality, and applicability to blood administration sets. No market estimates, market shares, forecasts, or company-specific claims are used here.

Conclusion: Reliable Devices Must Be Matched With Reliable Systems

Blood administration sets occupy a critical position in transfusion safety, connecting sterile product design with blood-bank controls, clinical technique, and hospital logistics. The most durable opportunities for improvement are likely to come from combining consistent device performance with stronger traceability, resilient sourcing, validated digital tools, and effective workforce training.

Regional and country conditions differ substantially, but the central priorities are consistent: protect patients, maintain sterility, support dependable workflows, comply with applicable requirements, and ensure availability when transfusion is needed. Leaders that treat the product as part of an integrated transfusion system-not as an isolated consumable-will be better positioned to improve safety, efficiency, and operational continuity.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Administration Set Market, by Product Type

• 7.1. Introduction
• 7.2. Closed System
• 7.3. Open System

8. Blood Administration Set Market, by Material

• 8.1. Introduction
• 8.2. Non-PVC
  • 8.2.1. EVA
  • 8.2.2. Polyethylene
• 8.3. PVC

9. Blood Administration Set Market, by Flow Rate

• 9.1. Introduction
• 9.2. High Flow
• 9.3. Low Flow
• 9.4. Medium Flow

10. Blood Administration Set Market, by Trigger Mechanism

• 10.1. Introduction
• 10.2. Electronic
• 10.3. Gravity

11. Blood Administration Set Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Care
• 11.3. Clinic
• 11.4. Hospital

12. Blood Administration Set Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Blood Administration Set Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Blood Administration Set Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Argon Medical Devices, Inc.
• 16.2. B. Braun Melsungen AG
• 16.3. Baxter International Inc.
• 16.4. Becton, Dickinson and Company
• 16.5. Cardinal Health, Inc.
• 16.6. Coloplast A/S
• 16.7. Fresenius Kabi AG
• 16.8. Grifols, S.A.
• 16.9. Haemonetics Corporation
• 16.10. ICU Medical, Inc.
• 16.11. McKesson Medical-Surgical Inc.
• 16.12. Medtronic plc
• 16.13. Mercury Medical LLC
• 16.14. Molnlycke Health Care AB
• 16.15. Nipro Corporation
• 16.16. Pfizer Inc.
• 16.17. Smiths Medical, Inc.
• 16.18. Teleflex Incorporated
• 16.19. Terumo Corporation
• 16.20. Unomedical by ConvaTec Group
• 16.21. Vyaire Medical, Inc.
• 16.22. Vygon SA

17. Key Experts